Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,169.07 +41.28 (+0.81%) Dow
38,774.92 +99.24 (+0.26%) Nasdaq
16,309.56 +153.23 (+0.95%) Bitcoin USD
62,961.52 -986.70 (-1.54%) CMC Crypto 200
1,358.61 +45.99 (+3.50%)
Eli Lilly and Company (LLY.F)
| Previous close | 682.50 |
| Open | 690.40 |
| Bid | 708.90 x 30000 |
| Ask | 710.50 x 30000 |
| Day's range | 685.70 - 710.90 |
| 52-week range | 384.00 - 742.80 |
| Volume | |
| Avg. volume | 631 |
| Market cap | 677.634B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 111.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.75 (0.67%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
